SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-20-015516
Filing Date
2020-11-04
Accepted
2020-11-04 16:36:04
Documents
16
Period of Report
2020-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mrtx-20201104.htm   iXBRL 8-K 38230
2 EX-99.1 exhibit991-q32020.htm EX-99.1 78406
8 miratilogo20191.jpg GRAPHIC 11133
  Complete submission text file 0001628280-20-015516.txt   268308

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20201104.xsd EX-101.SCH 2418
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20201104_cal.xml EX-101.CAL 710
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20201104_def.xml EX-101.DEF 1647
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20201104_lab.xml EX-101.LAB 21488
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20201104_pre.xml EX-101.PRE 11092
9 EXTRACTED XBRL INSTANCE DOCUMENT mrtx-20201104_htm.xml XML 9098
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 201287201
SIC: 2834 Pharmaceutical Preparations